So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...

On the forefront of healthcare change, turning innovative science into value for patients: Astellas at ASCO 2025 At this year ...

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

Healthcare generates massive volumes of data daily – from electronic health records and insurance claims to genomic research ...

KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...

Medical research charities LifeArc and Genetics Alliance UK have issued a call to the government to topple obstacles impeding ...

President Donald Trump took time out from the 4th July celebrations in the US to sign his One Big, Beautiful Bill Act (OBBBA) ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

The One Big Beautiful Bill (BBB), which passed (PDF) by a 51-50 vote with Vice President JD Vance casting the tie-breaker, ...

In today's healthcare landscape, there is a pressing need for quantitative methodologies that include the patients' ...

The weather was hot in London for this year’s LSX World Congress – but what was the atmosphere like at Europe’s leading partnering, strategy, and investment event?

A European pharma trade organisation has said that a new strategy launched by the EU to bolster the region's standing in life ...